Matthew B. Klein Ptc Therapeutics, Inc. (PTCT) insider trading activity

Matthew B. Klein is CHIEF EXECUTIVE OFFICER of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 225,807 shares of PTCT, which is worth approximately $10.2 Million. The most recent transaction as insider was on Apr 19, 2024, when has been sold 3,361 shares (Common Stock) at a price of $24.89 per share, resulting in proceeds of $83,655. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 226K

0% 3M change

26.89% 12M change

Total Value Held $10.2 Million

Matthew B. Klein Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 19 2024	SELL Open market or private sale	$83,655 $24.89 p/Share	3,361 Reduced 1.47%	225,807 Common Stock
Apr 17 2024	SELL Open market or private sale	$32,857 $25.14 p/Share	1,307 Reduced 0.57%	229,168 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	70,000 Added 23.3%	230,475 Common Stock
Jan 09 2024	SELL Open market or private sale	$157,901 $29.01 p/Share	5,443 Reduced 3.28%	160,475 Common Stock
Jan 08 2024	SELL Open market or private sale	$64,067 $28.64 p/Share	2,237 Reduced 1.33%	165,918 Common Stock
Jan 05 2024	SELL Open market or private sale	$274,405 $27.15 p/Share	10,107 Reduced 5.67%	168,155 Common Stock
Dec 28 2023	BUY Grant, award, or other acquisition	-	75,000 Added 29.65%	177,961 Common Stock
Apr 18 2023	SELL Open market or private sale	$63,020 $52.04 p/Share	1,211 Reduced 1.17%	102,645 Common Stock
Apr 18 2023	BUY Grant, award, or other acquisition	-	26,000 Added 20.02%	103,856 Common Stock
Jan 11 2023	SELL Open market or private sale	$99,543 $44.36 p/Share	2,244 Reduced 2.8%	77,856 Common Stock
Jan 10 2023	SELL Open market or private sale	$97,579 $42.93 p/Share	2,273 Reduced 2.76%	80,100 Common Stock
Jan 09 2023	SELL Open market or private sale	$30,453 $41.66 p/Share	731 Reduced 0.88%	82,373 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	26,000 Added 23.83%	83,104 Common Stock
Apr 19 2022	SELL Open market or private sale	$38,140 $42.52 p/Share	897 Reduced 1.56%	56,564 Common Stock
Jan 07 2022	SELL Open market or private sale	$29,853 $38.52 p/Share	775 Reduced 4.5%	16,461 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	41,000 Added 41.64%	57,461 Common Stock
Apr 20 2021	SELL Open market or private sale	$77,537 $47.25 p/Share	1,641 Reduced 8.89%	16,809 Common Stock
Apr 19 2021	SELL Open market or private sale	$41,378 $48.17 p/Share	859 Reduced 4.45%	18,450 Common Stock
Jan 15 2021	SELL Open market or private sale	$297,087 $69.09 p/Share	4,300 Reduced 18.21%	19,309 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	$167,614 $38.98 p/Share	4,300 Added 15.41%	23,609 Common Stock
Jan 08 2021	SELL Open market or private sale	$384,450 $69.9 p/Share	5,500 Reduced 22.17%	19,309 Common Stock
Jan 08 2021	BUY Exercise of conversion of derivative security	$214,390 $38.98 p/Share	5,500 Added 18.15%	24,809 Common Stock
Jan 07 2021	SELL Open market or private sale	$268,056 $68.98 p/Share	3,886 Reduced 16.75%	19,309 Common Stock
Jan 07 2021	BUY Exercise of conversion of derivative security	$151,476 $38.98 p/Share	3,886 Added 14.35%	23,195 Common Stock
Jan 06 2021	BUY Grant, award, or other acquisition	-	9,000 Added 31.79%	19,309 Common Stock

Also insider at

CLPT

ClearPoint Neuro, Inc. Healthcare

Director

MBK

Matthew B. Klein

CHIEF EXECUTIVE OFFICER

South Plainfield, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTCT shares.

Notify only if

Value

Insider Trading

Get notified when an Ptc Therapeutics, Inc. insider buys or sells PTCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to PTC THERAPEUTICS, INC.

Track Activities on PTCT

Account